WELCOME TO The PHARMACEUTICAL REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Adare Pharma Solutions | December 02, 2021
Adare Pharma Solutions ("Adare"), a technology-driven contract development and manufacturing organization (CDMO), announced the acquisition of Frontida BioPharm ("Frontida"), a vertically integrated CDMO focused on oral formulations. The acquisition reinforces Adare's commitment to transform drug delivery by providing world class solutions from product development through commercial scale manufacturing and packaging. Adare's portfolio of offerings for its custom...
Asymchem | September 17, 2021
Asymchem today announced a strategic partnership agreement to provide LaNova Medicines with one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration.
The collaboration between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives. This partnership will take full advantage of Asymchem's recently co...
PharmaNewsIntelligence | April 07, 2020
ASHP recently urged the Trump administration to take action to address shortages of supportive ventilator drugs as the number of confirmed COVID-19 cases continues to rise. The American Society of Health-System Pharmacists (ASHP) recently called on the Trump Administration to address shortages of supportive ventilator drugs as COVID-19 continues to infect more patients. In an official letter to Vice President Mike Pence, ASHP requested the administration release drugs from the Strategic Na...
BioSpace | February 27, 2020
With the acquisition of San Diego-based PvP Biologics and a recent deal with COUR Pharmaceuticals, Takeda Pharmaceutical is looking to become a world leader in the treatment of celiac disease and other gastrointestinal disorders. Asit Parikh, the head of Takeda’s Gastroenterology Therapeutic Area Unit told BioSpace in an email that the acquisition of PvP and its celiac asset Kuma062, now known as TAK-062, as well last fall’s acquisition of the license for a first-in-class celiac trea...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE